Breast cancer endocrine therapy adherence in health professional shortage areas: Unique effects on patients with mental illness

被引:4
|
作者
Haskins, Cole B. [1 ,2 ,3 ]
McDowell, Bradley D. [4 ]
Carnahan, Ryan M. [1 ]
Fiedorowicz, Jess G. [1 ,5 ,6 ,7 ]
Wallace, Robert B. [1 ]
Smith, Brian J. [4 ,8 ]
Chrischilles, Elizabeth A. [1 ]
机构
[1] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA
[2] Univ Iowa, Med Scientist Training Program, Iowa City, IA USA
[3] Univ Colorado, Dept Psychiat, Aurora, CO USA
[4] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
[5] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[6] Ottawa Hosp, Ottawa, ON, Canada
[7] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[8] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA
关键词
Mental illness; Breast cancer; Adherence; Access to care; Endocrine therapy; Shortage area; ADJUVANT HORMONAL-THERAPY; PRIMARY-CARE; MEDICATION ADHERENCE; CLINICAL-PRACTICE; DEPRESSION; NONADHERENCE; WOMEN; DISCONTINUATION; SCHIZOPHRENIA; MANAGEMENT;
D O I
10.1016/j.jpsychores.2020.110294
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Evaluate whether breast cancer endocrine therapy adherence is affected by access to primary and mental health care, particularly among at-risk patients with mental illness. Methods: The study included 21,892 SEER-Medicare women aged 68 or older with stage I-IV ER+ breast cancer, 2007 to 2013. Patient home counties during breast cancer diagnosis, if evaluated for HPSA care shortage status, were categorized as least, moderate, or highest shortage; unevaluated counties (no known shortage) were a fourth category. Endocrine therapy initiation and discontinuation were analyzed with Cox regression, and daily adherence with longitudinal linear regression. Results: After multivariate adjustment, patients in high primary care shortage counties were less likely to initiate endocrine therapy, reference least shortage [HR 0.92 (95% CI 0.86-0.97)]. Unevaluated counties had more oncologists per capita, fewer residents below the federal poverty level, and higher incomes. Mental health shortages were not associated with outcomes, however subgroups living in unevaluated counties were less likely to discontinue: patients with bipolar and psychotic disorders [discontinuation HR 0.35 (95% CI 0.17-0.73)], substance use [HR 0.48 (95% CI 0.24-0.95)], anxiety disorders [HR 0.56 (95% CI 0.35-0.90)]. Conclusions: Poor primary care access was associated with a lower likelihood of initiating endocrine therapy but living in counties without established mental health shortages may reduce the harmful association between mental illness and incomplete treatment receipt. Patients with mental illness may be more equipped to complete cancer treatment if given better mental health care access, suggesting a need for care coordination between primary and mental health care.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Assessing Adherence to Adjuvant Hormone Therapy in Breast Cancer Patients in Routine Clinical Practice
    Camejo, Natalia
    Castillo, Cecilia
    Tambasco, Clara
    Strazzarino, Noelia
    Requena, Nicolas
    Peraza, Silvina
    Boronat, Anna
    Herrera, Guadalupe
    Esperon, Patricia
    Cuello, Mauricio
    Krygier, Gabriel
    WORLD JOURNAL OF ONCOLOGY, 2023, 14 (04) : 300 - 308
  • [22] Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor?
    Wuensch, P.
    Hahne, A.
    Haidinger, R.
    Meissler, K.
    Tenter, B.
    Stoll, C.
    Senf, B.
    Huebner, J.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (01) : 55 - 60
  • [23] Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions
    Rassy, Elie
    Bardet, Aurelie
    Bougacha, Omar
    Gantzer, Laurene
    Lekens, Beranger
    Delaloge, Suzette
    Andre, Fabrice
    Michiels, Stefan
    Pistilli, Barbara
    JAMA NETWORK OPEN, 2022, 5 (12) : E2244849
  • [24] The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients
    Farias, Albert J.
    Hansen, Ryan N.
    Zeliadt, Steven B.
    Ornelas, India J.
    Li, Christopher I.
    Thompson, Beti
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (07): : 708 - 715
  • [25] Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer
    Lambert, Leah K.
    Balneaves, Lynda G.
    Howard, A. Fuchsia
    Chia, Stephen L. K.
    Gotay, Carolyn C.
    CURRENT ONCOLOGY, 2021, 28 (02) : 1472 - 1482
  • [26] Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer
    Bright, Emma E.
    Petrie, Keith J.
    Partridge, Ann H.
    Stanton, Annette L.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (02) : 243 - 251
  • [27] Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
    Reeder-Hayes, Katherine E.
    Troester, Melissa A.
    Wheeler, Stephanie B.
    ONCOLOGIST, 2021, 26 (11) : 910 - 915
  • [28] Correspondence Between Objective and Self-reported Endocrine Therapy Adherence Among Women With Breast Cancer
    Bright, Emma E.
    Stanton, Annette L.
    ANNALS OF BEHAVIORAL MEDICINE, 2019, 53 (09) : 849 - 857
  • [29] Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
    Ziller, V.
    Kalder, M.
    Albert, U. -S.
    Holzhauer, W.
    Ziller, M.
    Wagner, U.
    Hadji, P.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 431 - 436
  • [30] Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution
    Hwang, Grace S.
    Paranjpe, Rutugandha
    Opsomer, Carine
    Lu, Kelvin
    Abajue, Uzoamaka
    Abughosh, Susan
    Zaghloul, Hanna
    Trivedi, Meghana, V
    CLINICAL BREAST CANCER, 2020, 20 (06) : 520 - 526